Novo Nordisk A/S, a leading global healthcare company, has been actively executing its share repurchase program, which was announced on August 7, 2024. The program is part of a larger plan to buy back shares worth up to DKK 20 billion over a 12-month period starting from February 6, 2024. As of September 13, 2024, Novo Nordisk has repurchased 12,235,249 B shares at an average price of DKK 881.30 per share, totaling DKK 10,782,912,990. The transactions made under this program are detailed on the company's website. With the recent purchases, Novo Nordisk now holds 13,563,880 B shares as treasury shares, which is 0.3% of the share capital. The company's total share count, including treasury shares, stands at 4,465,000,000. Novo Nordisk's shares are traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange.

Novo Nordisk A/S, a leading global healthcare company, has been actively executing its share repurchase program, which was announced on August 7, 2024. The program is part of a larger plan to buy back shares worth up to DKK 20 billion over a 12-month period starting from February 6, 2024. As of September 13, 2024, Novo Nordisk has repurchased 12,235,249 B shares at an average price of DKK 881.30 per share, totaling DKK 10,782,912,990. The transactions made under this program are detailed on the company's website. With the recent purchases, Novo Nordisk now holds 13,563,880 B shares as treasury shares, which is 0.3% of the share capital. The company's total share count, including treasury shares, stands at 4,465,000,000. Novo Nordisk's shares are traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange.